PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16735966-5	2006	RESULTS: 5"-nucleotidase activity in diabetic patients before treatment with gliclazide was 1.61 +/- 0.16 nmol/min/10(6) lymphocytes, and was significantly (P < 0.01) increased compared with the level in healthy controls.	Gliclazide	77-87	5'-nucleotidase ecto	Homo sapiens	9-24	
16735966-0	2006	Lymphocyte ecto-5"-nucleotidase in obese type 2 diabetic patients treated with gliclazide.	Gliclazide	79-89	5'-nucleotidase ecto	Homo sapiens	11-31	
16735966-2	2006	The aim of this study was to assess the effect of the sulfonylurea drugs gliclazide and glibenclamide on lymphocyte ecto-5"-nucleotidase of type 2 diabetic patients.	Gliclazide	73-83	5'-nucleotidase ecto	Homo sapiens	116-136	
16735966-6	2006	After three months of gliclazide treatment, ecto-5"-nucleotidase activity fell significantly by 47.39% and 36% in unstimulated Con A- and PMA-stimulated lymphocytes, respectively.	Gliclazide	22-32	5'-nucleotidase ecto	Homo sapiens	44-64	
16735966-10	2006	CONCLUSION: These results show that gliclazide treatment inhibits the activity of lymphocyte ecto-5"-nucleotidase and presumably de-creases the concentration of adenosine at the cell surface.	Gliclazide	36-46	5'-nucleotidase ecto	Homo sapiens	93-113